Invesco Ltd. Has $114.28 Million Position in Doximity, Inc. $DOCS

Key Points

• Invesco Ltd. has increased its stake in Doximity, acquiring 696,923 shares to total 1,969,326 shares, representing a 54.8% increase in ownership during the first quarter.
• Recent transactions by company insiders show substantial selling activity, with $2.14 million worth of shares sold in the last 90 days, highlighting a decrease in their holdings.
• Doximity's stock price has seen a rise of 2.5% recently, standing at $65.12, as analysts continue to adjust their price targets, with a consensus rating of "Moderate Buy."

Invesco Ltd. raised its holdings in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 54.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,969,326 shares of the company's stock after purchasing an additional 696,923 shares during the quarter. Invesco Ltd. owned approximately 1.05% of Doximity worth $114,280,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Amalgamated Bank lifted its holdings in Doximity by 0.3% during the 1st quarter. Amalgamated Bank now owns 60,928 shares of the company's stock valued at $3,536,000 after purchasing an additional 186 shares during the last quarter. Greenleaf Trust lifted its holdings in Doximity by 5.4% during the 1st quarter. Greenleaf Trust now owns 4,492 shares of the company's stock valued at $261,000 after purchasing an additional 230 shares during the last quarter. Spire Wealth Management lifted its holdings in Doximity by 73.2% during the 1st quarter. Spire Wealth Management now owns 615 shares of the company's stock valued at $36,000 after purchasing an additional 260 shares during the last quarter. Allworth Financial LP lifted its holdings in Doximity by 104.0% during the 1st quarter. Allworth Financial LP now owns 563 shares of the company's stock valued at $32,000 after purchasing an additional 287 shares during the last quarter. Finally, Fielder Capital Group LLC lifted its holdings in Doximity by 5.8% during the 1st quarter. Fielder Capital Group LLC now owns 5,806 shares of the company's stock valued at $337,000 after purchasing an additional 318 shares during the last quarter. Institutional investors and hedge funds own 87.19% of the company's stock.

Doximity Price Performance

DOCS stock traded down $1.8570 during midday trading on Tuesday, reaching $64.0730. The company had a trading volume of 214,743 shares, compared to its average volume of 2,332,548. The company has a market capitalization of $12.00 billion, a price-to-earnings ratio of 64.07, a price-to-earnings-growth ratio of 4.10 and a beta of 1.36. The stock has a 50 day moving average price of $60.18 and a 200-day moving average price of $60.32. Doximity, Inc. has a 1-year low of $35.32 and a 1-year high of $85.21.

Doximity (NASDAQ:DOCS - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.36 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.05. Doximity had a return on equity of 21.75% and a net margin of 36.60%.The business's revenue was up 15.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.28 earnings per share. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. As a group, research analysts anticipate that Doximity, Inc. will post 0.99 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on DOCS. Bank of America lifted their target price on Doximity from $55.00 to $62.00 and gave the stock a "neutral" rating in a report on Wednesday, June 25th. Wells Fargo & Company lifted their target price on Doximity from $55.00 to $62.00 and gave the stock an "equal weight" rating in a report on Monday, August 4th. Canaccord Genuity Group lifted their target price on Doximity from $50.00 to $59.00 and gave the stock a "hold" rating in a report on Friday, August 8th. KeyCorp lifted their target price on Doximity from $65.00 to $70.00 and gave the stock an "overweight" rating in a report on Monday, July 14th. Finally, Evercore ISI raised Doximity from an "in-line" rating to an "outperform" rating and lifted their target price for the stock from $50.00 to $70.00 in a report on Wednesday, July 9th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and ten have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $66.21.

Insiders Place Their Bets

In other Doximity news, Director Regina M. Benjamin sold 10,000 shares of the business's stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00. Following the completion of the transaction, the director owned 16,618 shares of the company's stock, valued at approximately $997,080. The trade was a 37.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Timothy S. Cabral sold 10,000 shares of the business's stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $60.00, for a total value of $600,000.00. Following the transaction, the director directly owned 6,360 shares of the company's stock, valued at approximately $381,600. The trade was a 61.12% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,000 shares of company stock valued at $2,140,940. 31.30% of the stock is currently owned by corporate insiders.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.